Immunotherapeutic approaches to Alzheimer's disease
- PMID: 14593170
- DOI: 10.1126/science.1088469
Immunotherapeutic approaches to Alzheimer's disease
Abstract
Although neurodegenerative diseases such as Alzheimer's disease are not classically considered mediated by inflammation or the immune system, in some instances the immune system may play an important role in the degenerative process. Furthermore, it has become clear that the immune system itself may have beneficial effects in nervous system diseases considered neurodegenerative. Immunotherapeutic approaches designed to induce a humoral immune response have recently been developed for the treatment of Alzheimer's disease. These studies have led to human trials that resulted in both beneficial and adverse effects. In animal models, it has also been shown that immunotherapy designed to induce a cellular immune response may be of benefit in central nervous system injury, although T cells may have either a beneficial or detrimental effect depending on the type of T cell response induced. These areas provide a new avenue for exploring immune system-based therapy of neurodegenerative diseases and will be discussed here with a primary focus on Alzheimer's disease. We will also discuss how these approaches affect microglia activation, which plays a key role in therapy of such diseases.
Similar articles
-
Novel approaches for immunotherapeutic intervention in Alzheimer's disease.Neurochem Int. 2006 Jul;49(2):113-26. doi: 10.1016/j.neuint.2006.03.019. Epub 2006 Jun 12. Neurochem Int. 2006. PMID: 16765487 Review.
-
Current progress in beta-amyloid immunotherapy.Curr Opin Immunol. 2004 Oct;16(5):599-606. doi: 10.1016/j.coi.2004.07.012. Curr Opin Immunol. 2004. PMID: 15342006 Review.
-
[Mucosal immunotherapy for alzheimer's disease with viral vectors].Nihon Shinkei Seishin Yakurigaku Zasshi. 2007 Apr;27(2):53-6. Nihon Shinkei Seishin Yakurigaku Zasshi. 2007. PMID: 17515110 Japanese.
-
Immunology and immunotherapy of Alzheimer's disease.Nat Rev Immunol. 2006 May;6(5):404-16. doi: 10.1038/nri1843. Nat Rev Immunol. 2006. PMID: 16639431 Review.
-
Inflammation and therapeutic vaccination in CNS diseases.Nature. 2002 Dec 19-26;420(6917):879-84. doi: 10.1038/nature01325. Nature. 2002. PMID: 12490962 Review.
Cited by
-
Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease.Arch Neurol. 2004 Dec;61(12):1859-64. doi: 10.1001/archneur.61.12.1859. Arch Neurol. 2004. PMID: 15596606 Free PMC article.
-
Surface plasmon resonance for the analysis of beta-amyloid interactions and fibril formation in Alzheimer's disease research.Neurotox Res. 2005;7(1-2):17-27. doi: 10.1007/BF03033773. Neurotox Res. 2005. PMID: 15639795 Review.
-
An amyloid beta vaccine that safely drives immunity to a key pathological species in Alzheimer's disease: pyroglutamate amyloid beta.Brain Commun. 2022 Feb 4;4(1):fcac022. doi: 10.1093/braincomms/fcac022. eCollection 2022. Brain Commun. 2022. PMID: 35479516 Free PMC article.
-
Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer's disease.ASN Neuro. 2010 Jul 12;2(3):e00037. doi: 10.1042/AN20100010. ASN Neuro. 2010. PMID: 20640189 Free PMC article.
-
The intricate role of CCL5/CCR5 axis in Alzheimer disease.J Neuropathol Exp Neurol. 2023 Oct 20;82(11):894-900. doi: 10.1093/jnen/nlad071. J Neuropathol Exp Neurol. 2023. PMID: 37769321 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
